Seeking to break a stalemate over pricey cystic fibrosis drugs, the U.K.’s National Health Service has offered Vertex Pharmaceuticals (VRTX) what it called the “largest ever financial commitment of its type” for the company’s medicines.

After more than two years of haggling, the NHS agreed to “expanded and immediate” access to a pair of existing drugs, Orkambi and Kalydeco, and a forthcoming medicine called Symdeco. The agency also committed to making a next-generation triple therapy available once it is licensed by the government.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy